Q2 FDA slate narrows

The next three months at the United States Food and Drug Administration are packed with six drug decisions, and five of the six are for narrow populations, pediatric expansions, or hard-to-treat conditions rather than mass-market primary-care launches. The dates run from April 13 to June 30, with focal segmental glomerulosclerosis, pediatric diabetes, smoking cessation, resistant hypertension, severe hypertriglyceridemia, and pediatric psoriasis all on the calendar. (hcplive.com) A Prescription Drug User Fee Act date is the agency’s target deadline for acting on a drug application, and that deadline often becomes the real finish line for launch teams, safety staff, and medical affairs groups. The Food and Drug Administration says the law was created in 1992 to fund and speed reviews, and the agency separately maintains databases for postmarketing requirements and current prescribing information after approval. (fda.gov 1) (fda.gov 2) (fda.gov 3) The first decision is due April 13 for sparsentan in focal segmental glomerulosclerosis, a rare kidney disease that HCPLive says affects more than 40,000 people in the United States and still has no approved drug therapy. In the Phase 3 DUPLEX study, sparsentan hit a protein-in-urine remission endpoint at 36 weeks but missed the main 108-week kidney-function slope endpoint, which makes this one a straight Food and Drug Administration judgment call on mixed evidence. (hcplive.com) (ir.travere.com) The second decision is due May 29 for Afrezza, an inhaled insulin that MannKind wants to expand to children and teens aged 4 to 17 years with diabetes. The pediatric INHALE-1 study missed noninferiority on hemoglobin A1c, which is the blood test that tracks average glucose over about three months, but the company says patients reported higher treatment satisfaction and less weight gain than with multiple daily injections. (hcplive.com 1) (hcplive.com 2) June is where the calendar bunches up. HCPLive lists four late-quarter decisions: cytisinicline on June 25 for smoking cessation, baxdrostat on June 29 for uncontrolled or treatment-resistant hypertension, and both olezarsen and roflumilast on June 30 for severe hypertriglyceridemia and pediatric plaque psoriasis. (hcplive.com) Cytisinicline is the most old-fashioned idea in the group and the newest commercial opportunity at the same time. Achieve Life Sciences says its ORCA Phase 3 program showed higher quit rates than placebo and lower nausea than older stop-smoking drugs, which is why this could become the first new smoking-cessation medicine in nearly 20 years if the Food and Drug Administration says yes on June 25. (hcplive.com) (ir.achievelifesciences.com) Baxdrostat is aimed at a huge disease area, but the filing is still a specialist story because it targets the patients whose blood pressure stays high after several drugs. AstraZeneca said the Phase 3 BaxHTN trial enrolled 796 patients and showed a 15.7 millimeter mercury drop in seated systolic blood pressure at the 2 milligram dose after 12 weeks, with the drug designed to block aldosterone synthase while sparing cortisol pathways. (astrazeneca-us.com) (hcplive.com) Olezarsen is even more specialized. Ionis says the Food and Drug Administration gave its supplemental application priority review for severe hypertriglyceridemia, with a June 30 date, after Phase 3 CORE and CORE2 data showed large triglyceride reductions at 6 months that were sustained through 12 months, and the drug works by targeting apolipoprotein C3, a liver-made protein that helps keep triglycerides high. (hcplive.com) (markets.financialcontent.com) Roflumilast is the quietest decision in the set because it is a label expansion, not a brand-new molecule, but pediatric dermatology approvals can still force fast changes in dosing guides, counseling language, and field education. Arcutis says roflumilast cream 0.3% is already approved for plaque psoriasis in patients aged 6 years and older, and the June 30 decision would extend use to children aged 2 to 5 years. (arcutis.com) (hcplive.com) That is why this quarter looks narrower than louder Food and Drug Administration calendars built around obesity, cholesterol, or other primary-care blockbusters. Nature’s Q2 preview separately flags bigger commercial names like orforglipron for obesity, but the six-decision list highlighted by HCPLive is concentrated in